Vincerx Pharma - VINC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 1,349.49 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$0.69
▼ -0.0001 (-0.01%)

This chart shows the closing price for VINC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vincerx Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VINC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VINC

Analyst Price Target is $10.00
▲ +1,349.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vincerx Pharma in the last 3 months. The average price target is $10.00, with a high forecast of $28.00 and a low forecast of $3.00. The average price target represents a 1,349.49% upside from the last price of $0.69.

This chart shows the closing price for VINC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Vincerx Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2022Chardan CapitalLower TargetBuy$4.00 ➝ $3.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
8/12/2022SVB LeerinkLower TargetOutperform$6.00 ➝ $5.00Low
6/8/2022Cantor FitzgeraldLower Target$22.00 ➝ $8.00Medium
6/7/2022B. RileyLower TargetBuy$12.00 ➝ $6.00High
6/7/2022Chardan CapitalLower TargetBuy$11.00 ➝ $4.00High
6/7/2022SVB LeerinkLower TargetOutperform$19.00 ➝ $6.00High
4/12/2022B. RileyLower Target$26.00 ➝ $12.00Medium
3/30/2022SVB LeerinkLower TargetOutperform$24.00 ➝ $20.00Low
3/30/2022Chardan CapitalLower Target$30.00 ➝ $14.00Low
3/29/2022Chardan CapitalReiterated RatingBuyLow
3/29/2022HC WainwrightBoost TargetBuy$25.00 ➝ $28.00Medium
3/22/2022Chardan CapitalReiterated RatingBuyMedium
1/14/2022HC WainwrightInitiated CoverageBuy$25.00High
12/23/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00High
12/17/2021Chardan CapitalReiterated RatingBuy$30.00Medium
12/14/2021SVB LeerinkReiterated RatingBuyHigh
11/1/2021SVB LeerinkInitiated CoverageOutperform$24.00High
9/13/2021LaidlawInitiated CoverageBuy$30.00Low
8/25/2021B. RileyInitiated CoverageBuy$26.00Medium
8/13/2021Chardan CapitalLower TargetBuy$33.00 ➝ $30.00High
1/6/2021Chardan CapitalInitiated CoverageBuy$33.00N/A
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Vincerx Pharma logo
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $0.69
Low: $0.66
High: $0.69

50 Day Range

MA: $0.98
Low: $0.67
High: $1.38

52 Week Range

Now: $0.69
Low: $0.65
High: $11.26

Volume

1,100 shs

Average Volume

194,378 shs

Market Capitalization

$14.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Vincerx Pharma?

The following Wall Street analysts have issued research reports on Vincerx Pharma in the last year: B. Riley, Cantor Fitzgerald, Chardan Capital, HC Wainwright, and SVB Leerink LLC.
View the latest analyst ratings for VINC.

What is the current price target for Vincerx Pharma?

5 Wall Street analysts have set twelve-month price targets for Vincerx Pharma in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 1,349.5%. HC Wainwright has the highest price target set, predicting VINC will reach $28.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $3.00 for Vincerx Pharma in the next year.
View the latest price targets for VINC.

What is the current consensus analyst rating for Vincerx Pharma?

Vincerx Pharma currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VINC will outperform the market and that investors should add to their positions of Vincerx Pharma.
View the latest ratings for VINC.

What other companies compete with Vincerx Pharma?

How do I contact Vincerx Pharma's investor relations team?

Vincerx Pharma's physical mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The company's listed phone number is 650-800-6676. The official website for Vincerx Pharma is vincerapharma.com. Learn More about contacing Vincerx Pharma investor relations.